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SUMMARY  
Objective: Depression is the most prevalent psychiatric disorder in persons with epilepsy 
(PWEs). Despite its major impact on quality of life and risk of suicide, most PWEs are not 
treated for depression. A current challenge in mental health care is how to close this treatment 
gap and increase access to psychological services. Psychological online interventions (POIs) 
have shown efficacy in improving depression among indi- viduals without neurologic disorders. 
This pilot study aimed to assess the feasibility and efficacy of a psychological online intervention 
for depression (Deprexis) in PWEs who have symptoms of depression.  
Methods: Participants with self-reported epilepsy and subjective complaints of depres- sive 
symptoms were randomized to an intervention condition (Deprexis) or to a wait- ing list control 
(WLC) condition. After 9 weeks, participants were invited to complete an online reassessment.  
Results: Relative to the waiting list group, program users experienced a significant symptom 
decline on the Beck Depression Inventory - I (BDI-I, primary outcome) with a moderate effect 
size in the complete observations analysis and a small effect size in the intention-to-treat 
analysis. Furthermore, there was a significant improvement with a moderate effect size on the 
“energy/fatigue” subscale of the Quality of Life In Epilepsy Inventory - 31 (QOLIE-31).  
Significance: The results of this trial suggest that POIs may be a feasible and beneficial tool for 
PWEs who have comorbid depressive symptoms.   
KEY WORDS: Depression, Epilepsy, Internet intervention, iCBT, Deprexis.  Depressive 
disorders are the most frequent comorbid psychological conditions in persons with 
epilepsy (PWEs), with lifetime prevalence rates of 30–35%.1  
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Depressive disorders are the most frequent comorbid psychological conditions in persons 
with epilepsy (PWEs), with lifetime prevalence rates of 30–35%.1 Patients with 
uncontrolled seizures are diagnosed with major depression twice as often as patients with 
controlled seizures.2 Depressive symptoms, as well as seizure worry, have a major impact 
on the quality of life of affected indi- viduals,3 irrespective of the type of recent epileptic 
seizures.4  
A recent systematic review suggests that psychological interventions, such as cognitive 
behavioral therapy (CBT), are effective if they are particularly focused on the reduction 
of depressive symptoms rather than on the reduction of sei- zure frequency.5 Given 
physician-related treatment barriers related to fears of lowering seizure threshold and 
adverse drug interactions between antidepressants and antiepileptic drugs (such as, 
reciprocal inhibitory or excitatory effects on drug metabolisms), 6 as well as reluctance 
among PWEs to engage in therapy because of fear of stigmatization,7 alter- native 
methods of delivering treatment are needed. In the past decade, technological advances in 
Internet-based com- munication have created the potential to make psychologi- cal 
services more convenient and accessible to consumers.8 PWEs are often interested in 
exploring novel approaches, but unfortunately, research on the applicability and efficacy 
of such approaches for depression in PWEs is rare,9 in con- trast to the well-grounded 
evidence on psychological online interventions (POIs) for depression in general. A meta- 
analysis that included seven randomized controlled trials (RCTs) of self-guided 
psychological interventions for depression (one self-help book and six Internet-based 
self- help programs based on CBT methods [iCBT]) confirmed their efficacy, 
demonstrating an average small effect (d = 0.28).10 A subsequent meta-analysis that 
included 19 studies on computer- and Internet-based interventions for depression (based 
on several psychological treatment approaches) supported these findings and reported a 
moder- ate posttreatment pooled effect size (d = 0.56).11 POIs for depression hold 
promise, both as self-help applications and as adjunctive therapies to usual care.12  
Trial objective  
This pilot study aimed to evaluate the feasibility and effi- cacy of a POI program for 
depression (Deprexis; see Inter- vention section) in individuals with epilepsy and 
comorbid depressive symptoms. The primary outcome of the study was depressive 
symptoms as assessed with the Beck Depression Inventory I (BDI-I; see the 
Questionnaires sec- tion). A secondary aim was to assess whether quality of life is 
improved by the intervention.  
Methods  
Recruitment  
Between May 2012 and July 2013, a patient database from the Epilepsy Center Alsterdorf 
was used to invite patients via mail. Further patients were invited via postings in 
moderated epilepsy-specific online forums (http:// forum.epilepsie-netz.de/ and 
http://www.epilepsie-onli- ne.de/forum/). Individuals without self-reported epilepsy 
diagnoses or depressive symptoms were excluded automati- cally from the online survey 
and were blocked from re-par- ticipation by means of “cookies.” Beyond that, self-
reported epilepsy diagnoses were externally validated based on an epilepsy-specific 
inventory, the Performance, Sociodemo- graphic Aspects, Subjective Estimation 
(PESOS) question- naire (see Questionnaires section), by conducting plausibility checks 
for each participant. The study invitation summarized the basic study design, and it was 
made clear that all participants would receive free-of-charge access to the online program 
(either immediately or at the end of the study), which would automatically expire after 
the intervention period of 9 weeks. No financial reimbursement was offered for study 
participation.  
Baseline assessment  
A Web-link in the postal and forum invitations directed potential participants to the 
baseline survey, which was implemented using the software package EFS Survey 
(www.unipark.info). The online survey program prevented multiple logins from the same 
computer to the baseline sur- vey by the use of “cookies.” We obtained an online 
informed consent for each participant in accordance with regulations by the Ethics 
Committee of the Medical Associ- ation, Hamburg. The baseline survey proceeded with 
sec- tions as follows: inquiry of sociodemographic information, clinical history (e.g., 
current treatments, psychiatric diagno- ses), a psychopathologic (e.g., depression), and a 
psycho- logical section (e.g., quality of life). The psychological and psychopathologic 
sections encompassed several question- naires that are described in detail in subsequent 
text. At the end of the survey, participants were required to enter their e-mail addresses. 
Completing the baseline survey required approximately 40 min.  
Inclusion and exclusion criteria  
Inclusion criteria were liberal because we aimed to acquire a clinically representative 
sample to maximize external validity and, thus, relevance for clinical practice.13 For 
example, although age and currently being in psycho- therapy or using pharmacologic 
treatment did not lead to exclusion, these variables were examined for their effect on 
outcomes. It was not our aim to verify a clinical diagnosis of depression, because we 
conducted our trial using low- threshold criteria including subclinical depressive symp- 
toms. The reason for low-threshold studies was to reach people that usually fall through 
the cracks of health care because of subclinical depressive symptoms or reluctance to 
undergo face-to-face treatments or diagnostic assess- ments.  
Individuals without self-reported epilepsy diagnoses, without self-reported depressive 
symptoms, and with acute suicidal ideation, and those lacking sufficient time to take part 
in the online program for 9 weeks, were excluded from participation. Reporting 
diagnoses of psychosis or bipolar disorder, as well as suicidality, led to immediate 
exclusion by means of a “trap door” in the survey program, which ter- minated the 
assessment by informing participants about the respective reasons for their exclusion. For 
subjects with sui- cidal tendencies, telephone numbers of institutions special- ized in the 
treatment of suicidality were displayed.  
Treatment allocation  
Included participants who provided their e-mail addresses at the end of the baseline 
survey were randomly allocated to the treatment or WLC group. Allocation was done in 
consecutive order using a computer-generated ran-  
dom number table. No stratification was applied. Partici- pants in the immediate 
treatment group received detailed instructions via e-mail on how to log into the Deprexis 
sys- tem using an access code that allowed full use of the pro- gram for the duration of 9 
weeks, starting at the time of registration. Those in the WLC condition (delayed treat- 
ment) received notice via e-mail that they were allocated to the control group and would 
receive their access code upon completion of the follow-up assessment 6 months later.  
Intervention  
This trial used the Internet-based program Deprexis,14 which is aimed at reducing 
symptoms of depression. It com- prised predominantly elements of CBT, such as 
cognitive restructuring and behavioral activation, and complements these with 
mindfulness and acceptance exercises, among others. Users interact with the program via 
a simulated dia- logue, in which they are continuously asked to select one of several 
response options and are presented with subsequent content that aims to match their 
expressed preferences and requirements. Depending on reading speed and each user’s 
individual path through the program, each module lasts approximately 10–60 min.  
Reassessment (after 9 weeks)  
Nine weeks after the baseline assessment, participants were sent an e-mail invitation to 
take part in the second evaluation that included a link directing them to the posttreatment 
survey. To achieve a high completion rate, up to three reminders were sent via e-mail if 
the partici- pants did not respond to the invitation e-mail. At the beginning of the 
posttreatment survey, participants were requested to enter the same e-mail address as in 
the baseline survey for identification and matching of pre- and postdata. The post 
assessment contained the same questionnaires as the baseline survey (see Questionnaires 
section). In addition, participants in the treatment condi- tion were asked questions 
relating to subjective appraisal of the program.  
Sample size  
Sample size calculation, performed using G*Power,15 revealed that 80 patients (full 
sample) would be neces- sary to detect a significant difference when assuming a 
medium–large effect size of treatment over the control condition at an a-level of 0.05 and 
a power of 0.95 (two-tailed; considering 25% dropout). Recruitment stopped after 81 
patients had completed the baseline survey. Three of those 81 were excluded prior to the 
baseline analyses, so that 78 participants remained in the sample. One of those three was 
lost due to technical issues with the survey program, and two others were excluded 
because they stated they had given untrue answers to some of the questions in the survey.  
Questionnaires  
The Beck Depression Inventory (BDI-I),16 which served as the primary outcome of the 
study, is a self-report ques- tionnaire containing 21 items. It represents a common 
instrument for the assessment of depression severity. Inter- nal consistency for both 
psychiatric and nonpsychiatric pop- ulations is above 0.8.16 The BDI was subdivided into 
three subscales: negative attitude toward self, performance impairment, and somatic 
symptoms.17  
The PESOS questionnaire for PWEs assesses individual impairment due to epilepsy.18 In 
addition to objective parameters, such as demographic data, seizure frequency, and 
further clinical aspects, subjective questions are posed that are focused on illness-specific 
difficulties and limita- tions, such as disability in everyday life, mobility and inde- 
pendent life, social relationships, physical and mental conditions, epilepsy-specific 
anxiety, stigma-related prob- lems, emotional adaptation, job-related difficulties, parent- 
related difficulties, and school-related difficulties. The internal consistency of the PESOS 
subscales is adequate (Cronbach’s a = 0.75–0.89), as well as the criterion-related validity 
with the Quality of Life in Epilepsy Inventory (QOLIE-31, see below) of r = 0.71. The 
questionnaire originally contains 58 items, but for the online survey of this trial, only 
those items that were deemed necessary to vali- date a diagnosis of epilepsy were used.18  
The World Health Organization (WHO) Quality of Life questionnaire (WHOQOL-
BREF) is an abbreviated 26-item version of the WHOQOL-100 that was developed by 
the WHOQOL Group in 1995 to measure quality of life in persons with physical or 
psychological illnesses, as well as in those without any health impairments. The measure 
cov- ers four domains: physical, psychological, social, and envi- ronmental quality of 
life.19  
The Quality of Life in Epilepsy Inventory (QOLIE-31)20 contains seven subscales that tap 
emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure 
worry, medication effects, and overall quality of life. The QOLIE-31 overall score is 
obtained by a weighted aver- age of the different dimensions that include 30 items in 
total.  
For participants who were assigned to the intervention group, additional questions 
relating to the subjectively per- ceived efficacy and feasibility of the program were posed. 
Further, several questions probed the intervention’s applica- bility to the specific issue of 
depressive symptoms in PWEs.  
Strategy of data analysis  
All statistical analyses were conducted blinded and by using IBM" SPSS" Statistics 22.0 
(Armonk, NY, U.S.A.) software. Complete observations analyses were conducted for 
participants using a linear mixed model (LMM) approach in view of statistical studies 
suggesting that an LMM yields higher power to detect group differences and can utilize 
all available data.21 All results are reported using restricted maximum likelihood (REML) 
estimation and the Satterthwaite approximation to calculate the denominator degrees of 
freedom. Following the advice of Barr et al.22 in terms of the random effects structure, for 
each result, the individual participant is utilized as a random intercept, and time between 
assessments in weeks is used as a random slope. The parameter estimate of interest for 
each model is the interaction term group (Deprexis vs. WLC) 9 time (baseline vs. post), 
which contains the information if a sig- nificant change between the two groups exists 
over time. Effect sizes are reported as Cohen’s d (d ≤ 0.2 % small effect, d ≤ 0.5 % 
moderate effect, 0.8 ≤ d % large effect).  
Results  
Baseline differences  
Sociodemographic and clinical baseline characteristics of each group are presented in 
Table 1. Randomization was generally successful because no significant differences 
between the intervention group and the control group emerged for most variables, except 
for age: F(1, 76) = 2.01, p = 0.048. Participants in the WLC group were, on average, 5 
years older (40 years; range 22–70) than participants in the intervention group (35 years; 
range 18–57). To take this group difference into account, the variable “age” was entered 
as a covari- ate in the statistical analyses.  
Approximately 75% of all subjects were female, 47% had at least high school education 
(13th grade), and 25% received some kind of psychotropic medication. With focus on 
antiepileptic medication, almost half of the anticonvulsive drugs were well-tolerated in 
both groups. Again, there was no difference between the WLC and the intervention group 
in terms of seizure type and frequency. On average, both groups had predomi- nantly 
minimal–mild depressive symptoms (BDI score ≤ 18) with an average BDI score of 19 
(range 2–40) in the WLC and 22 (range 5–49) in the intervention group  
(see Table 2). Almost half of the participants (47.4%) reported receiving some kind of 
depression treatment at baseline.  
Group comparisons  
Completion  
The overall completion rate for the main outcome at post assessment was 72%, with no 
statistically significant differ- ence between the intervention group (63%) and the control 
group (80%): v2(1) = 2.00, p = 0.157. Three participants were missing because one 
subject withdrew consent during the course of the trial, and in two cases there was a 
delivery failure of the invitations to the via email postassessment. Another subject 
cancelled halfway through the online survey, so corresponding data are available for the 
BDI but not for the rest of the measures.  
Statistical analyses  
Analyses on complete observations were conducted for the primary and secondary 
outcomes. The main effect of the covariate, age, did not yield significance in any of the 
analy- ses. Results are summarized in Table 2, indicating that patients in the intervention 
group showed a significantly greater symptom reduction on the BDI-I total score than 
subjects in the WLC, with a moderate effect size F(1, 55.96) = 7.14; p = 0.01; d = 0.46. 
The extent of this effect size corresponded with a substantial improvement of 6.24 BDI 
points, on average, for the intervention group. However, the WLC group also improved 
slightly (1.41 BDI points) across time (see Table 2).  
In addition to the analyses utilizing all available data, intention-to-treat (ITT) analyses 
were performed for the pri- mary outcome (BDI-I) and for all secondary outcomes with 
the last observation carried forward (LOCF) method, that is, the baseline observation. 
Results, displayed in the final col- umn of Table 2, did not change except for the BDI 
subscale “negative attitude toward self,” which was not significant anymore.  
Table 1. Sociodemographic and clinical background information of WLC and intervention group 
at baseline  
There was no significant difference in the quality-of-life gain between the intervention 
group and the WLC over time as measured using the four domains of the WHOQOL- 
BREF. There was also no significant group difference over time in the epilepsy-specific 
quality of life measure, the QOLIE-31, F(1, 76) = 0.098; p = 0.755; d = 0.04, but in the 
subscale “energy/fatigue” we found a significant differ- ence between intervention group 
and WLC with a moderate effect size, F(1, 76) = 4.274; p = 0.042; d = 0.32, as well as a 
statistical trend for the subscale “social function,” F (1, 76) = 2.812; p = 0.098; d = 0.21 
(Table 3).  
Subjective appraisal  
Table 4 provides data on the retrospective appraisal of the program from participants who 
were randomized into the intervention group and had logged into the program at least 
once. Most of the participants were satisfied with the program, would use it again, and 
appraised it as suitable for depressive symptoms that accompany epilepsy. Although 
participants see the program as a suitable adjunct to their medical treatment and a tool to 
bridge waiting time for psy- chotherapy, only a minority found the program appropriate 
as a substitute for psychotherapy. A slight majority reported that the program should be 
better adapted to the special needs of PWEs. Most suggestions in this respect referred to 
the wish of including more epilepsy-related topics: how to deal with stresses and strains 
that go along with seizures, how to react to the stigmatization of PWEs and psycho-edu- 
cation regarding the relationship of epilepsy and depression.  
Discussion  
The study investigated the efficacy and feasibility of a psychological online intervention 
for depression (Deprexis) in PWEs and comorbid depressive symptoms. The comple- tion 
rate (73%) was a little lower than in equivalent trials with samples of individuals with 
depression (81.9%)23 or individuals with depression associated with multiple sclero- sis 
(79%).24  
The majority of PWEs appraised the intervention pro- gram as “good” and “helpful to 
treat depressive symptoms” (see Table 2). Subjective appraisal was confirmed in the 
complete analyses for the BDI-I, where significant improve- ments with small to 
moderate effect sizes emerged for the total score, as well as the subscales “negative 
attitude towards self” and “performance impairment.” The signifi- cant results for the 
BDI total score were reproduced in an ITT (LOCF) analysis with small effect sizes. The 
effect was not due to concomitant treatment; groups did not differ in treatment (or 
treatment changes) with antiepileptic drugs during the intervention period. We consider 
this symptom reduction to be a meaningful change, which implies that a larger trial on 
PWEs with comorbid depressive symptoms using Deprexis or other online treatment 
programs should be conducted in the future (including analyses on the mechanisms of 
efficacy, and the impact of adherence and attitudes toward psychotherapy on efficacy, as 
well as effectiveness trials in natural settings).  
 
Table 2. Group comparisons on the primary outcome measure (BDI) for baseline, end point, and 
across time  
Table 3. Group comparisons on the secondary outcome measure QOLIE-31 for baseline, end 
point, and across time  
On the measures tapping epilepsy-specific quality of life (QOLIE-31) and quality of life 
in general (WHOQOL- BREF), significant improvement emerged on only one sub- scale 
of the QOLIE-31 (“energy/fatigue”). This result might be due to the behavioral 
activation, as well as the physical exercise and lifestyle modification modules of 
Deprexis. This improvement is in line with the symptom reduction in the BDI 
“performance impairment” item “fatigue.”17 We speculate that no improvements on other 
subscales of the QOLIE-31 emerged due to a lack of epilepsy-related themes covered by 
Deprexis.  
In their subjective appraisal of Deprexis, most partici- pants found that the program 
should be adapted to the spe- cial needs of PWEs with respect to involving more 
epilepsy-related topics. “Tailoring”25 Deprexis to PWEs, could increase the acceptability 
as well as the effectiveness of the intervention in this particular patient group.  
Some limitations of this pilot study need to be addressed before turning to the 
conclusions. First, the recruitment pro- cess was very slow, indicating that PWEs had no 
great inter- est in either online trials or the intervention. Still, subjective appraisal of the 
intervention was good, which speaks for the need for different recruitment strategies in 
further trials.  
Second, diagnosis of both epilepsy and depressive symp- toms relied on self-report 
measures instead of direct contact. Self-assessments conducted online have been shown 
to be valid26 and are therefore used with increasing frequency. A recent meta-analysis 
concluded that self-reports yield more conservative estimates of treatment efficacy than 
clinician ratings.27  
A further problem concerns a possible recruitment bias. Because of the self-selectivity 
nature of online studies, it could be that participants were exceedingly motivated or 
suitable for psychological online interventions. Such inter- ventions might be particularly 
attractive for people who are well-versed in using the Internet, or those with a preference 
for alternative treatment approaches, a reluctance to seek direct treatment, or 
dissatisfaction with conventional inter- ventions.27 To avoid this bias, more trials in 
natural settings are warranted, in light of the promising results of the pri- mary 
effectiveness trials.28  
Further problems that often accompany online trials and interventions are high dropout 
rates and difficulty assessing the reasons for attrition. Regarding the present trial, there 
was an absolute, but not statistically signifi- cant difference in dropout rates between 
groups, such that fewer participants dropped out in the control group. Therefore, 
assumptions for the LOCF method (missing values are missing completely at random) 
were not vio- lated. This was also supported by conducting all analyses using a per-
protocol method (not presented here) that did not alter any of the results. Nevertheless, 
one should bear in mind that future research should address any potential dropout bias 
rigorously, either by implementing an active control or by other means. Although, we 
tried to prevent dropouts in this study by sending e-mail reminders, it must be noted that 
completion rates were slightly worse than in an equivalent study by our research group in 
par- ticipants with depression without neurologic disorders,23 as well as in depressed 
participants with depression and 24 other neurologic disorders.  
The present article reports an interim analysis. Accord- ingly, we are well aware of the 
rising probability of a type-1 error for the upcoming analysis of follow-up data. In light of 
this, the present results have to be considered preliminary and should be investigated 
further when all data are avail- able using appropriate methods to control for the higher 
type-1 error rate. Secondly, because this trial is of a preli- minary nature, in the future our 
results need to be replicated in individuals with confirmed diagnoses of epilepsy and 
control groups of PWEs without depressive symptoms, PWEs with depression, and 
depressed patients without epi- lepsy.  
To conclude, the present study contributes to a growing  empirical basis highlighting the 
benefits of POI for depression. Interventions such as Deprexis may help to close the  
existing treatment gap due to their accessibility and efficacy.14,23,29 It is also important to 
note that most Internet  interventions that claim to reduce depressive symptoms  have no 
evidence base at all and should be tested in independent randomized controlled trials 
before they can be regarded as safe and efficacious. Effective POI programs  for people 
with symptoms of depression can potentially  have a large impact at a population health 
level—even with 30 symptoms. Face-to-face therapy should still be recom- mended as the 
standard for depression treatment, but POIs can be regarded either as feasible alternatives 
or as a possi- ble adjunct to traditional treatment approaches.  
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